# Principles of Clinical Pharmacology Syllabus 2019-2020

## Module 1: Introduction to Clinical Pharmacology

<table>
<thead>
<tr>
<th>Lectures</th>
<th>Post-Lecture Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction to Module 1 - Dr. Craig Thomas</td>
<td></td>
</tr>
<tr>
<td>Introduction to Clinical Pharmacology and Therapeutics - Dr. Juan J.L. Lertora</td>
<td>Case Study: Steady-State Calculation</td>
</tr>
<tr>
<td>Introduction to Pharmacology, Drug Development and Clinical Pharmacology - Dr. William D. Figg</td>
<td>Understanding the Basics of Pharmacology</td>
</tr>
<tr>
<td>Practical Pharmacology - Dr. Anne Zajicek</td>
<td>Case Study: Practice with Prescriptions</td>
</tr>
<tr>
<td>Biochemical Mechanisms for Drug Toxicity - Dr. A. Beasley Green</td>
<td>Case Study: Statins &amp; Hepatotoxicity</td>
</tr>
<tr>
<td>Ethics in Pediatric Clinical Pharmacology - Dr. Donna L. Snyder</td>
<td>Case Study: Pediatric Extrapolation</td>
</tr>
<tr>
<td>Ethics in Adult Clinical Pharmacology - Dr. Ezekiel J. Emanuel</td>
<td>Principles of Ethics</td>
</tr>
</tbody>
</table>

## Module 2: Pharmacokinetics

<table>
<thead>
<tr>
<th>Lectures</th>
<th>Post-Lecture Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction to Module 2 - Dr. Anne Zajicek</td>
<td></td>
</tr>
<tr>
<td>Drug Absorption and Bioavailability – Dr. Jan Beumer</td>
<td>Case Study: The Impact of Food on Bioavailability</td>
</tr>
<tr>
<td>Use of Positron Emission Tomography (PET) in Pharmacokinetics – Dr. Robert Innis</td>
<td>Basics of PET in PK</td>
</tr>
<tr>
<td>Compartmental Analysis of Drug Distribution – Dr. Arthur Atkinson</td>
<td>Case Study: Effect of Protein Binding on Vd</td>
</tr>
<tr>
<td>Noncompartmental vs. Compartmental Approaches to Pharmacokinetic Analysis – Dr. Paolo Vicini</td>
<td>Case Study: Nonlinear PK Calculation</td>
</tr>
<tr>
<td>Chemical Analysis of Drugs and Metabolites – Dr. Sanford P. Markey</td>
<td>Mass Spectrometry</td>
</tr>
<tr>
<td>Pharmacokinetics/Pharmacodynamics of Protein Drugs – Dr. Jürgen Venitz</td>
<td>Case Study by Dr. Jürgen Venitz: PK/PD of TNF Blockers</td>
</tr>
</tbody>
</table>

## Module 3: Drug Metabolism and Transport

<table>
<thead>
<tr>
<th>Lectures</th>
<th>Post-Lecture Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction to Module 3 – Dr. Lisa M. Cordes</td>
<td></td>
</tr>
<tr>
<td>Pathways of Drug Metabolism – Dr. Sanford P. Markey</td>
<td>Case Study by Dr. Lionel D. Lewis: “Victims &amp; Perpetrators” in Therapeutics</td>
</tr>
<tr>
<td>Drug Transporters in ADME and Drug Action - Dr. Joseph Ware</td>
<td>Case Study by Dr. Jomy M. George: Transporter Mediated Drug-Drug Interactions</td>
</tr>
<tr>
<td>P-Glycoprotein and Drug Transport Part 1 - Dr. Michael Gottesman</td>
<td>Case Study: Cabazitaxel &amp; P-Glycoprotein</td>
</tr>
<tr>
<td>P-Glycoprotein and Drug Transport Part 2 - Dr. Matthew Hall</td>
<td>Case Study: The Mystery of Loperamide</td>
</tr>
<tr>
<td>Membrane Transport - Dr. Kathy Giacomini</td>
<td>Membrane Transporters in Drug Development</td>
</tr>
<tr>
<td>Drug Transport Across the Blood Brain Barrier - Dr. Sadhana Jackson</td>
<td>Permeability of the Blood Brain Barrier</td>
</tr>
</tbody>
</table>

## Module 4: Pharmacokinetics and Drug Therapy in Special Populations

<table>
<thead>
<tr>
<th>Lectures</th>
<th>Post-Lecture Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction to Module 4 - Dr. Bruce Waldrop</td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetics in Patients Requiring Renal Replacement Therapy Part 1 - Dr. Arthur Atkinson</td>
<td>Pitfalls in the Calculation of Hemodialysis Clearance</td>
</tr>
<tr>
<td>Pharmacokinetics in Patients Requiring Renal Replacement Therapy Part 2 - Dr. Gregory Susla</td>
<td>Continuous Renal Replacement Therapy: Who, When, Why, How</td>
</tr>
<tr>
<td>The Liver and Drugs - Dr. Jürgen Venitz</td>
<td>Case Study: Dose Adjustments Based on Child-Pugh Score</td>
</tr>
<tr>
<td>Drug Therapy in Pregnant and Nursing Women - Dr. Anne Zajicek</td>
<td>Case Study: Risks of Phenobarbital During Lactation</td>
</tr>
<tr>
<td>Developmental and Pediatric Pharmacology - Dr. John N. van den Anker</td>
<td>Developmental Changes That Influence Drug Disposition</td>
</tr>
<tr>
<td>Drug Therapy in the Geriatric Population - Dr. Darrell R. Abernethy</td>
<td>Case Study: DOACs in the Elderly</td>
</tr>
<tr>
<td>Pharmacokinetics and Obesity – Dr. Manjunath Pai</td>
<td>Case Study: Body Size Calculations</td>
</tr>
</tbody>
</table>
### Module 5: Assessment of Drug Effects

<table>
<thead>
<tr>
<th>Lectures</th>
<th>Post-Lecture Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction to Module 5 - Dr. Terry Seaton</td>
<td></td>
</tr>
<tr>
<td>Biomarkers of Drug Effects - Dr. Robert Schuck</td>
<td>Pharmacodynamic/Response Biomarkers</td>
</tr>
<tr>
<td>Pharmacodynamic and Pharmacokinetic Modeling of Data – Dr. Joga Gobburu</td>
<td>PK/PD Modeling Exercise by Dr. Cody J. Peer</td>
</tr>
<tr>
<td>Disease Progression Models - Dr. Diane Mould</td>
<td>Key Concepts of Disease Progression Modeling</td>
</tr>
<tr>
<td>Role of Pharmacodynamics with Drug Development - Dr. James Doroshow</td>
<td>Pharmacodynamic &amp; Proof of Mechanism Biomarkers</td>
</tr>
<tr>
<td>Immunotherapeutics - Dr. James Gulley</td>
<td>Case Study by Dr. Lisa M. Cordes: Immunotherapy-Related Adverse Events</td>
</tr>
</tbody>
</table>

### Module 6: Drug Discovery and Development

<table>
<thead>
<tr>
<th>Lectures</th>
<th>Post-Lecture Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction to Module 6 - Dr. William Zamboni</td>
<td></td>
</tr>
<tr>
<td>Drug Discovery - Dr. Edward Sausville</td>
<td>Drug Discovery Basics</td>
</tr>
<tr>
<td>Quantitative Systems Pharmacology - Dr. D. Lansing Taylor</td>
<td>Integrating Diverse Data Sources into Computational Models</td>
</tr>
<tr>
<td>Computational Methods of Drug Discovery and Design - Dr. Glen Kellogg</td>
<td>Computational Methods Key Definitions</td>
</tr>
<tr>
<td>Combinatorial Drug Screening - Dr. Craig Thomas</td>
<td>Case Study: BRAF &amp; MEK Inhibitors in Melanoma</td>
</tr>
<tr>
<td>Animal Scale Up and First-in-Human Studies - Dr. Jerry Collins</td>
<td>Estimating the Starting Dose in FiH Studies</td>
</tr>
<tr>
<td>Dose Selection and Optimization in the Adult Population - Dr. Yaning Wang</td>
<td>Case Study: Secukinumab Dosing Optimization</td>
</tr>
<tr>
<td>Drug Development in the Pediatric Population - Dr. Anne Zajicek</td>
<td>Clinical Research Involving Children</td>
</tr>
<tr>
<td>Drug Formulation and Delivery - Dr. Ping Gao</td>
<td>Understanding Drug Formulations</td>
</tr>
<tr>
<td>Natural Products - Dr. Barry O'Keefe</td>
<td>Decisions on Screening Natural Products</td>
</tr>
<tr>
<td>T-Cell Therapies: Principles and Practice - Dr. James Yang</td>
<td>Structures of Adoptive Cell Therapies</td>
</tr>
<tr>
<td>Pharmacokinetic and Pharmacodynamic Considerations in the Development of Macromolecules - Dr. Pamela Garzone</td>
<td>Case Study: Pharmacokinetics of Monoclonal Antibodies</td>
</tr>
<tr>
<td>Design of Clinical Drug Development Programs - Dr. Christopher D. Breder</td>
<td>Clinical Drug Development Path</td>
</tr>
<tr>
<td>FDA Approval Considerations - Dr. Paul Kluetz</td>
<td>Discussion on Clinical Trial Endpoints by Dr. Barry Goldspiel</td>
</tr>
</tbody>
</table>

### Module 7: Pharmacogenomics and Pharmacotherapy

<table>
<thead>
<tr>
<th>Lectures</th>
<th>Post-Lecture Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction to Module 7 - Dr. Elvin Price</td>
<td></td>
</tr>
<tr>
<td>Pharmacometabolomics: Implications for Clinical Pharmacology - Dr. Richard Weinshilboum</td>
<td>Case Study: SSRIs &amp; Pharmacometabolomics</td>
</tr>
<tr>
<td>Pharmacogenomics - Dr. Michael Pacanowski</td>
<td>Case Study: Ivacaftor &amp; CFTR</td>
</tr>
<tr>
<td>Dose Modifications Based on Pharmacogenomics Research - Dr. Howard McLeod</td>
<td>Case Study: Dosing Guidelines for Azathioprine &amp; TPMT</td>
</tr>
<tr>
<td>Clinical Pharmacogenomics Testing - Dr. Mary Relling</td>
<td>Gene/Drug Pairs</td>
</tr>
<tr>
<td>Clinical Drug Interactions - Dr. Sarah Robertson</td>
<td>Case Study: Clinical Implications of Grapefruit Juice</td>
</tr>
<tr>
<td>Clinical Assessment of Adverse Drug Reactions - Dr. Christopher D. Breder</td>
<td>Case Study: Describing Adverse Events Using CTCAE</td>
</tr>
<tr>
<td>Post-Marketing Drug Safety Surveillance - Dr. Timothy Jancel</td>
<td>Case Study: MedWatch Voluntary Reporting</td>
</tr>
<tr>
<td>Quality Assurance for Drug Therapy - Dr. Charles Daniels</td>
<td>Medication Use Evaluation</td>
</tr>
</tbody>
</table>